pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
BRISTOL MYERS SQUIBB · news · pharmadog
← back to BRISTOL MYERS SQUIBB
News mentioning BRISTOL MYERS SQUIBB
199
stories
18h
Cellectis cans allogeneic CAR-Ts to hop aboard in vivo bandwagon
fiercebiotech
19h
5 drugmakers chasing Merck and Moderna in the cancer vaccine race
biospace
3d
BioNTech sets survival standard in hard-to-treat cancer ahead of pivotal readout
fiercebiotech
3d
In first interview as FDA oncology chief, Angelo de Claro vows to ‘continue the innovation’ behind OCE legacy
fiercebiotech
4d
Chutes & Ladders—Longtime Takeda R&D chief to depart next June
fiercebiotech
4d
Tyra shares slip as bladder cancer responses fall short of investor expectations
biospace
5d
Merck adds 53 to New Jersey chopping block
biospace
5d
BMS clinches pivotal win for myeloma CAR T in ‘key derisking event’
biospace
5d
Beeline Medicines reports promising Phase 2 lupus data
endpoints
5d
A new immuno-oncology play raises $225M for a next-generation drug
biopharma dive
5d
Beeline flies into phase 3 as oral lupus drug soars past placebo
fiercebiotech
5d
Solstice rises with $225M series A to advance next-gen CTLA-4 immunotherapy into phase 2
fiercebiotech
6d
Roivant surges on ‘exceptional’ results; Bristol Myers touts first-of-its-kind CAR-T therapy
biopharma dive
6d
Bristol Myers’ pivotal CAR-T multiple myeloma trial hits primary endpoint
fiercebiotech
6d
AI will only revolutionize drug discovery and development if we play to its strengths
biospace
10d
Biotech is back, with H1 progress smoothing glide path through end of year: Truist
biospace
10d
STAT+: We’re reading about a Bristol CAR-T trial pause, Pfizer offloading a shelved candidate, and more
stat
11d
Akeso, Summit cancer drug confirms lung cancer survival benefit
biopharma dive
11d
Replimune’s melanoma drug would have been rejected again if not for senior CBER official
biospace
11d
AbbVie’s bispecific T-cell engager shows promise in ph. 3 multiple myeloma trial
fiercebiotech
11d
GSK pens $1.3B Hutchmed deal for early-stage KRAS-EGFR cancer asset
fiercebiotech
12d
Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts
biopharma dive
12d
Novartis’ and BMS’ paused CAR T trials, RevMed’s pancreatic cancer approval, more MFN deals
biospace
12d
Stripped of AstraZeneca safety net, BMS could face ‘carnage’ if high-risk clinical trial fails
biospace
13d
Alumis’ TYK2 drug fails in key lupus study
biopharma dive
13d
STAT+: Pharmalittle: We’re reading about Novartis and Bristol pausing cell therapy trials, a $480K cancer drug, and more
stat
13d
ArsenalBio sacrifices ‘majority’ of staff in pivot to in vivo CAR T
biospace
13d
9 midsize drugmakers climb aboard Trump’s MFN train
biospace
13d
Novartis pauses CAR T studies due to 3 deaths; BMS follows suit after safety events
biospace
13d
ArsenalBio sheds most of staff in pivot to in vivo CAR-T
fiercebiotech
← prev
page 1 of 7
next →
